NCT05646004 is a NA clinical trial of Cataract surgery in Senile Cataract, sponsored by Carl Zeiss Meditec AG.

Who is sponsoring NCT05646004?

NCT05646004 is sponsored by Carl Zeiss Meditec AG.

What drugs are being tested in NCT05646004?

Interventions in NCT05646004: Cataract surgery.

What condition does NCT05646004 study?

NCT05646004 studies Senile Cataract.

Is NCT05646004 still recruiting?

NCT05646004 is currently status unknown. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT05646004

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

621 Real World Study

Status unknown NA Last updated 10 January 2023

What this trial tests

NA trial testing Cataract surgery in Senile Cataract in 105 participants. Status unknown.

Timeline

9 January 2023

Primary endpoint
1 September 2024

1 September 2024

Quick facts

Lead sponsor	Carl Zeiss Meditec AG
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	105
Start date	9 January 2023
Primary completion	1 September 2024
Estimated completion	1 September 2024
Sites	1 location across China

Drugs / interventions tested

Cataract surgery — full drug profile →

Conditions studied

Senile Cataract — all drugs for Senile Cataract →

Sponsor

Carl Zeiss Meditec AG — full company profile →

Who can join

18 and older, any sex, with Senile Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is evaluating the clinical safety and effectiveness of 621, after cataract surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Cataract surgery

Trials testing the same drug.

NCT06505434 — A Dynamic Study of Pupil Diameter After Artificial Lens Implantation in Patients With High Myopia · not yet recruiting
NCT06400745 — Clareon PanOptix Pro vs. Clareon PanOptix - Study A · NA · completed
NCT05776095 — Evaluation of Safety and Performance Outcomes of Eyedeal IOL Implantation After Cataract Removal · NA · unknown
NCT05796674 — Clareon IOL Retrospective Data Collection · completed
NCT04074954 — A (Prospective/Pilot) Study Evaluating the Effect of Cataract Surgery on the Daily Activity Levels of Elderly Patients · withdrawn

Other Carl Zeiss Meditec AG trials

Trials by the same sponsor.

NCT07471295 — Toric Performance And Constant Evaluation · Phase 4 · not yet recruiting
NCT07297719 — Evaluation of Glistening, Visual Outcomes and General Safety 24 Months Post-IOL Implantation · completed
NCT06192901 — Safety and Performance of Hydrophobic and Hydrophilic Intraocular Lenses After Bilateral Cataract Surgery · completed
NCT06247683 — Study to Confirm Safety and Performance of a New Multifocal IOL · NA · completed
NCT05201027 — Study to Optimize the IOL Constant of a New Multifocal Intraocular Lens · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05646004 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Carl Zeiss Meditec AG
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05646004.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing